Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Cell Reports

Volumn 18, Issue 1, 2017, Pages 248-262

  Charoentong, Pornpimol ^a   Finotello, Francesca ^a   Angelova, Mihaela ^a   Mayer, Clemens ^a   Efremova, Mirjana ^a   Rieder, Dietmar ^a   Hackl, Hubert ^a   Trajanoski, Zlatko ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

cancer germline antigens; neoantigens; predictive marker; tumor infiltrating lymphocytes

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; COHORT ANALYSIS; GENETIC DATABASE; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; IMMUNOGENICITY; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; MACHINE LEARNING; MALIGNANT NEOPLASM; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR ESCAPE; CELL CYCLE CHECKPOINT; GENETICS; GENOMICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MUTATION; NEOPLASM; PROCEDURES; PROGNOSIS;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE CHECKPOINTS; CTLA-4 ANTIGEN; GENOMICS; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; MACHINE LEARNING; MUTATION; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85009106590     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.12.019     Document Type: Article

References (39)

1. Angelova, M., Charoentong, P., Hackl, H., Fischer, M.L., Snajder, R., Krogsdam, A.M., Waldner, M.J., Bindea, G., Mlecnik, B., Galon, J., Trajanoski, Z., Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol., 16, 2015, 64.
2. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
3. Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pagès, F., Trajanoski, Z., Galon, J., ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25 (2009), 1091–1093.
4. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
5. Blank, C.U., Haanen, J.B., Ribas, A., Schumacher, T.N., CANCER IMMUNOLOGY. The “cancer immunogram”. Science 352 (2016), 658–660.
6. Breiman, L., Random forests. Mach. Learn. 45 (2001), 5–32.
7. Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H., Holt, R.A., Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24 (2014), 743–750.
8. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161 (2015), 1681–1696.
9. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 (2014), 676–690.
10. Covre, A., Coral, S., Nicolay, H., Parisi, G., Fazio, C., Colizzi, F., Fratta, E., Di Giacomo, A.M., Sigalotti, L., Natali, P.G., Maio, M., Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. OncoImmunology, 4, 2015, e1019978.
11. Gajewski, T.F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., Harlin, H., Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213 (2006), 131–145.
12. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
13. Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
14. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
15. Hackl, H., Charoentong, P., Finotello, F., Trajanoski, Z., Computational genomics tools for dissecting tumour-immune cell interactions. Nat. Rev. Genet. 17 (2016), 441–458.
16. Hakimi, A.A., Reznik, E., Lee, C.H., Creighton, C.J., Brannon, A.R., Luna, A., Aksoy, B.A., Liu, E.M., Shen, R., Lee, W., et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29 (2016), 104–116.
17. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
18. Iglesia, M.D., Parker, J.S., Hoadley, K.A., Serody, J.S., Perou, C.M., Vincent, B.G., Genomic analysis of immune cell infiltrates across 11 tumor types. J. Natl. Cancer Inst., 108, 2016 djw144.
19. Landau, D.A., Carter, S.L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M.S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152 (2013), 714–726.
20. Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.
21. Li, B., Severson, E., Pignon, J.C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J.C., Rodig, S., et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol., 17, 2016, 174.
22. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
23. Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.H., Pagès, F., Galon, J., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29 (2011), 610–618.
24. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., Alizadeh, A.A., Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12 (2015), 453–457.
25. Nielsen, M., Lundegaard, C., Blicher, T., Lamberth, K., Harndahl, M., Justesen, S., Røder, G., Peters, B., Sette, A., Lund, O., Buus, S., NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE, 2, 2007, e796.
26. Oikonomou, E., Koustas, E., Goulielmaki, M., Pintzas, A., BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 5 (2014), 11752–11777.
27. Pitt, J.M., Vétizou, M., Daillère, R., Roberti, M.P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I.G., Chamaillard, M., Kroemer, G., Zitvogel, L., Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44 (2016), 1255–1269.
28. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
29. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
30. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
31. Rubio-Perez, C., Tamborero, D., Schroeder, M.P., Antolín, A.A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., Lopez-Bigas, N., In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27 (2015), 382–396.
32. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M., Wolchok, J.D., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33 (2015), 1889–1894.
33. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
34. Spencer, K.R., Wang, J., Silk, A.W., Ganesan, S., Kaufman, H.L., Mehnert, J.M., Biomarkers for immunotherapy: current developments and challenges. Am. Soc. Clin. Oncol. Educ. Book 35 (2016), e493–e503.
35. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., Mesirov, J.P., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
36. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
37. van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L.J., Behjati, S., Hilkmann, H., El Atmioui, D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31 (2013), e439–e442.
38. Witkiewicz, A.K., McMillan, E.A., Balaji, U., Baek, G., Lin, W.C., Mansour, J., Mollaee, M., Wagner, K.U., Koduru, P., Yopp, A., et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun., 6, 2015, 6744.
39. Wolchok, J.D., PD-1 blockers. Cell, 162, 2015, 937.